Metabolic syndrome and risk of endometrial cancer in postmenopausal women: a prospective study
Obesity is a strong risk factor for endometrial cancer, but it is unclear whether metabolic syndrome (MetS) contributes to endometrial cancer risk over and above the contribution of obesity.
We examined the association of MetS and its components with risk of endometrial cancer in a sub-cohort of 24,210 women enrolled in the Women’s Health Initiative cohort study. Two variants of the National Cholesterol Education Program Adult Treatment Panel III definition of the MetS were used: one including and one excluding waist circumference (WC). Cox proportional hazards models were used to estimate the association of the study exposures with disease risk.
When WC was included in the definition, MetS showed an approximately two-fold increase in endometrial cancer risk (HR 2.20; 95% CI 1.61–3.02); however, when WC was excluded, MetS was no longer associated with risk. We also observed that women with hyperglycemia, dyslipidemia and hypertension, in combination, had almost a twofold increased risk of endometrial cancer, independent of WC (HR 1.94; 95% CI 1.09, 3.46). Glucose, and, in particular, WC and body mass index were also positively associated with risk.
Our findings suggest that MetS may predict risk of endometrial cancer independent of obesity among women with the remaining four Mets components.
KeywordsMetabolic syndrome Obesity Abdominal adiposity Endometrial cancer Postmenopausal women
Conception and design: TER, GCK, RA; Development of methodology: GCK, TER, RA; Acquisition of data: GCK; Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): GCK, TER, RA, MYK; Writing, review, and/or revision of the manuscript: GCK, TER, RA, MYK, RAW, AHS, JW-W, GYFH, KWR, LHK, JL, JB-D, MSS, HS, SW-S.
This work was supported by institutional funds from the Albert Einstein College of Medicine.
Compliance with ethical standards
Conflict of interest
No potential conflicts of interest were disclosed.
- 5.Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Tjønneland A et al (2007) Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 14:755–767CrossRefGoogle Scholar
- 15.Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M et al. Outcomes ascertainment and adjudiciationmethods in the Women’s Health Initiative. Ann Epidemiol. 13:S122–8Google Scholar
- 19.Kabat GC, Kim MY, Lane DS, Zaslavsky O, Ho GYF, Luo J et al (2018) Serum glucose and insulin and risk of cancers of the breast, endometrium, and ovary in postmenopausal women. Eur J Cancer Prev 27:261–268Google Scholar
- 20.Marshall S, Bacote V, Traxinger RR (1991) Discovery of a metabolic pathway mediating glucose induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 266:4706–4712Google Scholar